Risks of using psilocybin in treatment of treatment-resistant depression
Journal of Education, Health and Sport – March 07, 2025
Source: DOAJ
Summary
As new treatments for treatment resistant depression are urgently needed, psilocybin shows promise. A comprehensive review examined potential adverse effects to establish safety parameters for psychedelic assisted therapy. Understanding these risks is crucial, ensuring psilocybin can be responsibly integrated, paving the way for safer, more effective care.
Abstract
Introduction As depression rates continue to rise globally, the need for more effective and innovative treatments has become increasingly urgent, highlighting the potential impact of psilocybin as a promising therapeutic option. However, to ensure its safe and effective integration into clinical practice, it is essential to establish robust safety parameters for its administration. This paper focuses on addressing the risks associated with psilocybin therapy. We believe this paper can help understand risks as a platform for safety based treatment. Material and Methods A comprehensive literature search was conducted using the PubMed and Google Scholar databases, supplemented by references cited in the initially identified articles. The search focused on studies and reviews addressing the challenges and risks associated with psilocybin use in the treatment of treatment-resistant depression (TRD).